alankravitz
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

alankravitz

Forum Replies Created

Viewing 1 reply thread
1 2 3
  • Replies
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:20 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:18 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:18 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:18 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:17 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:17 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:17 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:15 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:15 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
      • May 15, 2013 at 7:15 pm
      alankravitz
      Participant
      Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.
Viewing 1 reply thread
1 2 3
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics